期刊文献+

四肢骨肉瘤保肢治疗的疗效观察 被引量:9

The effect of limb-salvage treatment of limb osteosarcoma
原文传递
导出
摘要 目的评价采用保肢和截肢术结合化疗对Ⅱ期四肢骨肉瘤患者的临床疗效。方法分析1996年1月~2007年7月山西医科大学第二医院骨科收治确诊的68例肢体骨肉瘤患者的临床资料,其中48例行保肢术治疗,20例行截肢术。术前、术后均进行化疗。63例患者获随访,随访时间6~63个月,平均38.5个月。将随访时间达3年的53例骨肉瘤患者分为保肢组和截肢组,以3年生存率、局部复发率以及术后的功能恢复评价为指标进行比较。结果在53例肢体骨肉瘤患者中,保肢组3年生存率为51.4%,局部复发率为8%,按照国际保肢协会推荐使用的肿瘤术后功能重建评价系统平均为26分。截肢组3年生存率为50%,局部复发率为6%,术后功能评分平均为12分。统计学检验比较保肢术和截肢术术后3年生存率无显著性差异(P>0.05)。结论在术前、术后辅助化疗的基础上,保肢组的3年生存率、局部复发率与截肢组相似,并且保肢术后功能恢复满意,故采用保肢术治疗同期肢体骨肉瘤患者疗效优于截肢术。 Objective To evaluate the effect of limb-salvage treatment and amputation combined with chemotherapy for stage II osteosarcoma of the extremities. Methods The clinical data of 68 patients who were diagnosed with limb steosarcoma were analyzed. Among them, 48 patients underwent limb-salvage surgery, and 20 patients underwent amputation. All patients underwent preoperative and postoperative chemotherapy. 63 patients were followed up for 6 to 63 months. The mean follow-up was 38.5 months. 53 patients (follow-up 〉3 years) were devided into limb-salvage treatment group and amputation treatment group. The two groups were compared with respect to 3-year survival rate, local recurrence rate and the functional evaluation of reconstructive procedures. The difference in 3-year survival rate of the two groups was compared by log-rank test. Results Among 53 patients, in the limb-salvage surgery group, the 3-year survival rate was 51.4%, the local recurrence rate was 8%, and the functional evaluation of reconstructive procedures after surgical treatment was 26 points. In amputation patients, the 3-year survival rate was 50%, the local recurrence rate was 6%, and the functional evaluation of reconstructive procedures after surgical treatment was 12 points. There was no significant difference between the two groups in 3-year overall survival rate (P〉0.05). Conclusions Combined with preoperative and postoperative chemotherapy, limb-salvage and amputation surgery would lead to a similar 3-year survival rate and local recurrence rate, and the functional evaluation of reconstructive procedures was satisfactory. The clinical outcome of limb-salvage treatment was superior to amputation treatment.
作者 赵毓军 吕智
出处 《中国骨肿瘤骨病》 2010年第2期136-139,共4页 Chinse Journal Of Bone Tumor And Bone Disease
关键词 骨肉瘤 保肢治疗 截肢术 化疗 Osteosarcoma Limb-salvage Amputation Chemotherapy
  • 相关文献

参考文献11

  • 1Ferrari S,Palmerini E.Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma.Curr Opin in Oncol,2007,19:341-346.
  • 2Ham S J,Schraffordt Koops H,van der Graaf WT,et al.Historical,current and future aspects of osteosarcoma treatment.Eur J Surg Oncol,1998,24:584-600.
  • 3胡永成,范顺武,郭卫,马宏庆.全国骨肉瘤保肢座谈会会议纪要[J].中华骨科杂志,2000,20(7):390-392. 被引量:38
  • 4郭卫.骨与软组织肿瘤术后功能重建的评估标准[J].中华骨科杂志,2001,21(10):635-636. 被引量:36
  • 5Grimer RJ,Taminiau AM,Cannon SR.Surgical outcomes in osteosarcoma.J Bone Joint Surg Br,2002,84:395-400.
  • 6Bacci G,Ferrari S,Lari S,et al.Osteosarcoma of the limb.Amputation or limb salvage in patients treated by neoadjuvant chemotherapy.J Bone Joint Surg Br,2002,84:88-92.
  • 7Picci P,Sangiorgi L,Rougraff BT,et al.Relationship of chemotherapy induced necrosis and surgical margins to local recurrence in osteosarcoma.J Clin Oncol,1994,12:2699-2705.
  • 8王鸥,王全明.新辅助化疗加保肢手术治疗肢体骨肉瘤[J].中国骨肿瘤骨病,2004,3(4):215-218. 被引量:5
  • 9Rosen G,Marcove RC,Caparros B,et al.Primary osteogenic sarcoma:the rationale for preoperative chemotherapy and delayed surgery.Cancer,1979,43:2163-2177.
  • 10Damron TA.Endoprosthetic replacement following limbsparing resection for hone sarcoma.Semin Surg Oncol,1997,13:3-10.

二级参考文献8

  • 1[1]Bramwell VH. The role of chemotherapy in the management of nonmetastatic operable extremity osteosarcoma. Semin Oncol, 1997,24:561 -571.
  • 2[2]Enneking WH,Dunham W,Gebhardt MC, et al. A system for the functional evaluation of reconstruction procedures after surgical treatment of tumors of the musculoskel ststem. Clin Orthop, 1993, (286):241 - 246.
  • 3[3]Lindner NJ, Ramm O, Hillmann A, et al. Limb salvage and outcome of osteosarcoma: the university of muenster experience. Clin Orthop,1999,(358) :83 -89.
  • 4[4]Goorin A, Baker A,Gieser P, et al. No evidence for improved event free survival (EFS) with presurgical chemotherapy (PRE) for nonmetastic extremity osteogenic sarcoma ( OGS ): preliminary results of randomized pediatric oncolong group (POG) trial 8651 [ abstract ]. Pro AM Soc Clin Oncol, 1995,6:329- 337.
  • 5[6]Picci P,Sangiorgi L,Rouaff BT, et al. Relationship of chemotherapyinduced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol, 1994,12:2699 - 2705.
  • 6[7]Rosen G,Caparros B,Huvos AG, et al. Cancer,1982,49:1221 -1230.
  • 7[8]Mankin HJ,Doppelt S,Tomford W. Clinical experience with allograft implantation: the firsl ten yrars. Clin Orthop, 1983, (174) :69 - 86.
  • 8杨迪生,范顺武,陶惠民,何荣新,叶招明,徐世伟,陈芳,黄宗坚.高温隔离灌注化疗在下肢骨与软组织肉瘤保肢治疗中的价值与限度[J].中国矫形外科杂志,1997,4(5):347-349. 被引量:13

共引文献75

同被引文献79

引证文献9

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部